Cho BC, Han JY, Kim SW, Lee KH, et al. A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol 2021 Dec 24. pii: S1556-0864(21)03403.
PMID: 34958928